Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Allergopharma

Status and phase: Completed; Phase 2

Conditions: Birch Pollen Allergy

Treatments: Biological: Recombinant birch pollen

Study type: Interventional

Funder types: Industry

Identifiers

NCT00266526

Al0303rB

Details and patient eligibility

About

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive RAST result to birch pollen
• Positive Skin Prick Test reaction to birch pollen
• positive nasal provocation test result to birch pollen extract

Exclusion criteria

• serious chronic diseases
• other relevant seasonal allergies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)